0001185185-17-002179.txt : 20171016 0001185185-17-002179.hdr.sgml : 20171016 20171016160925 ACCESSION NUMBER: 0001185185-17-002179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171016 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20171016 DATE AS OF CHANGE: 20171016 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIZONE INTERNATIONAL INC CENTRAL INDEX KEY: 0000753772 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870412648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 002-93277-D FILM NUMBER: 171138805 BUSINESS ADDRESS: STREET 1: 350 EAST MICHIGAN AVENUE STREET 2: SUITE 500 CITY: KALAMAZOO STATE: MI ZIP: 49007 BUSINESS PHONE: (269) 202-5020 MAIL ADDRESS: STREET 1: 350 EAST MICHIGAN AVENUE STREET 2: SUITE 500 CITY: KALAMAZOO STATE: MI ZIP: 49007 FORMER COMPANY: FORMER CONFORMED NAME: MADISON FUNDING INC DATE OF NAME CHANGE: 19860413 8-K 1 medizone8k101617.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2017
 
Medizone International, Inc.
(Exact name of registrant as specified in its charter)
 
Nevada
 
2-93277-D
 
87-0412648
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
350 East Michigan Avenue, Suite 500
Kalamazoo, MI
 
49007
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (269) 202-5020
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.

On October 16, 2017, Medizone International, Inc. (“Company”) issued a press release announcing that the Company is now allowed to place the “CE” Mark on the AsepticSure® System for distribution in the European Union and its member states.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits

Exhibit
 Number
 
Description
 
 
 
99.1
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDIZONE INTERNATIONAL, INC.
 
 
 
 
Date: October 16, 2017
 
 
 
 
 
/s/ David A. Dodd
 
 
 
 
 
 
David A. Dodd
 
 
 
 
 
 
Chief Executive Officer

 
 
 EX-99.1 2 ex99-1.htm EX-99.1

Exhibit 99.1
 
The AsepticSure® Disinfection System, a revolutionary disinfection technology, Receives CE Mark

Kalamazoo, Michigan, October 16, 2017.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure® System for distribution in the European Union (EU) and its member states.

Medizone’s CEO, David A. Dodd commented, “The receipt of CE Mark approval is a significant and important step in the commercial development of AsepticSure® in key European markets, which is an integral element in our international growth strategy for this game-changing product and technology.  The CE Mark validates product adherence to the European Commission's quality assurance and safety requirements, while providing an unprecedented solution to ensuring disinfection of all pathogens.”

The European market for disinfection technologies represents a multi-billion-dollar market for both healthcare and non-healthcare use that has consistently demonstrated rapid adoption of innovative technologies compared to other industrialized markets.  Well established distribution channels within member countries present numerous opportunities to accelerate the growth of AsepticSure® in the market.

Further commenting on the significance of the availability of the AsepticSure® System for the European market, Michael E. Shannon, M.A., M.Sc., M.D., Medizone President & Director, Medical Affairs, noted, “Using conventional double cleaning practices or disinfection technology, it is simply not possible to achieve even a 3-log (99.9%) bactericidal and virucidal kill throughout an entire targeted room.  AsepticSure® routinely achieves a minimum kill at least a thousand times greater than conventional cleaning methods across all pathogens on all surfaces within a contaminated space.  We are delighted to see our advanced technology now available to the European market and look forward to the acceptance and adoption of AsepticSure® within both healthcare and non-healthcare environments throughout Europe.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.


Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.


For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com